Recombinant human stem cell factor (SCF), the ligand for c-kit, has been shown t o stimulate increased numbers of hematopoietic progenitor cells of multiple types t o circulate in the blood of baboons, but it was not known if the cells stimulated t o circulate by SCF contained cells capable of engrafting and rescuing lethally irradiated baboons. Peripheral blood mononuclear cells (PBMNC) were collected by leukapheresis from four untreated control baboons and from three baboons on the 10th or 1 l t h day of treatment with SCF (200 pg/kg/d). All animals were transplanted with 1.00 t o 1.04 x 10*/kg of cryopreserved autologous PBMNC after treatment with a single dose of 1,020 cGy total body irradiation (TBI). Three animals were transplanted with PBMNC that had been collected during SCF treatment, 24 t o 38 days after the last dose of SCF. Rapid trilineage engraftment was documented by bone marrow biopsy in all three. The mean time t o a total white blood cell count (WBC) 500/pL, WBC 2 l,OOO/pL, and an absolute neutrophil count (ANC) z EMATOPOIETIC colony-forming progenitor cells
H (CFC) and cells capable of engrafting and rescuing
lethally irradiated recipients have been detected in the circulation of several mammalian However, these cells are present at a much lower frequency in the circulation than in marrow. The number of CFC as well as cells that mediate engraftment have been reported to increase in the circulation transiently following perturbation of hematopoiesis by treatment with either chemotherapeutic agents, hematopoietic growth factors, or
We have previously shown that the ligand for c-kit, referred to as either stem cell factor (SCF) or mast cell growth factor, stimulates both in vitro and in vivo hematopoiesis in baboons.23 This factor has a significant effect on the circulating levels of CFC with differing proliferative and differentiative potentials in v i t r~.~~,~~ It was not known if the cells stimulated to enter the circulation under the influence of SCF were capable of reconstituting hematopoiesis in vivo. The present studies showed that administration of SCF causes an increase in the number of CFC and CD34+ cells in circulation and that peripheral blood mononuclear cells (PBMNC) isolated from SCF-treated animals can engraft lethally irradiated baboons. In contrast, the same number of PBMNC isolated from the blood of untreated animals was inadequate to rescue animals from the lethal effects of total body irradiation (TBI).
MATERIALS AND METHODS

Animals.
Healthy juvenile baboons (Papio cynocephalus cynocephalus or P cynocephalus anubis) of either sex and weighing between 7.1 and 12.7 kg (mean ? SEM = 10.4 ? 0.7 kg) were housed at the University of Washington Regional Primate Research Center under American Association for Accreditation of Laboratory Animal Care approved conditions. Studies were conducted under Institutional Review Board and Animal Care and Use Committee approved protocols. All animals were provided with water, biscuits, and fruit ad libitum throughout the study. Before transplantation, all animals had central venous catheters placed for use with a tether system?6 Animals were treated with prophylactic broad spectrum antibioticsz7 until they were transfusion independent, any infectious complications had resolved, and their venous catheters were removed. All animals were treated with a single dose of 1,020 cGy TBI administered from opposing 60Cobalt sources at 7 ~G y / m i n .~~ Immediately after completing the TBI, cryopreserved autologous PBMNC were thawed and infused. The dose of cells given, based on the cell count and differentials of the leukapheresed cells at the time of cryopreservation, was calculated to give a dose of 1 x lo8 PBMNC/kg. For bone marrow (BM) biopsies and peripheral venous blood draws, animals were anesthetized as previously described. Colony-forming cell assays. Baboon peripheral blood buRy coat cells were isolated, residual red blood cells were lysed with ammonium chloride buffer, and the cells were cultured in 35-mm culture dishes (Nunc, Naperville, IL) at 1.0 to 0.3 x 1@/mL per culture dish. All cells were cultured in two layer agar cultures for colony-forming units granulocyte-macrophage (CFU-GM), burstforming units-erythroid (BFU-E), and high proliferative potential colony-forming cells (HPP-CFC), as previously d e s~r i b e d .~~,~~ Recombinant human growth factors used to stimulate colony formation included interleukin-3 (IL-3) (100 ng/mL), granulocytemacrophage colony-stimulating factor (GM-CSF) (100 ng/mL), IL-6 (100 ng/mL), erythropoietin (Epo) (4 U/mL), and SCF (100 ng/mL) (purified material supplied by Amgen, Thousand Oaks, CA), or for HPP-CFC cultures, GM-CSF (30 ng/mL), IL-1p (20 ng/mL), IL-3 (20 ng/mL), and SCF (100 ng/mL). Cultures were incubated at 37°C in 5% 0~~5 % CO2, humidified incubator. At day 14 of culture CFU-GM and BFU-E were enumerated. HPP-CFC were enumerated after 21 days of culture. All cultures were performed in triplicate unless otherwise indicated. Colony-forming cell data in Table 1 are reported as the mean f one standard deviation per 1 x lo5 peripheral blood buRy coat cells.
Leukapheresis was performed with animals under general anesthesia.Z6 The cephalic vein and femoral artery were canulated with 16-gauge teflon catheters. A Cobe 2997 blood cell separator was primed with 300 mL of heparinized baboon blood that had been irradiated (2,526.5 rad, 815 rad per minute in a 157Cesium source) and passed through a Pall RClOO leukocyte removal filter (Pall Biomedical, East Hills, NY). Before leukapheresis each animal was primed with 1,000 U of heparin. Leukapheresis was performed at a rate of 40 mL/min and a bowl speed of 850 to 900 rpm for 1.5 to 2.0 hours. During leukapheresis, anticoagulation was maintained by infusion of 0.9% saline with 0.5% citrate and 22 U of heparin/mL at a rate of 2 mL/min. Cells were collected at 1 to 2 mL/min into a bag containing 20 mL of acid citrate dextrose anticoagulant. After the leukapheresis was completed the arterial and venous catheters were removed and the vessels ligated. SCF-treated animals were leukapheresed 1.7 f 0.2 hours (mean f SEM), resulting in the collection of 182 f 22 mL containing 41.4 15.8 X lo6 cells/mL that were 90% f 9% mononuclear cells. Control animals were leukaplieresed 1.8 2 0.1 hours resulting in the collection of 182 f 22 mL containing 32.6 ? 8.9 X lo6 cells/mL that were 93% f 6% mononuclear cells. More cells were collected from both experimental (5.5 f 1.4-fold, range 3.1-to 7.9-fold) and control animals (5.6-f 1.2-fold, range 3.0-to 7.9-fold) than were required for transplantation.
Cells collected were pelleted at 1,000 rpm and then resuspended in TC199 (GIBCO, Grand Island, NY) supplemented with 40%
(vol/vol) heat-inactivated fetal bovine serum (FBS) (Hyclone, Logan, UT) to a final volume of 50 mL. This was mixed with 50 mL of TC199 40% FBS 20% dimethyl sulfoxide (DMSO) and then frozen in 50" aliquots in bags using a programmed freezer (Cryomed, New Baltimore, MI). Cells were thawed in a 37°C water bath and infused without prior washing into irradiated recipients. After thawing, 97% ? 8% (mean f SEM) of the total nucleated cells cryopreserved were recovered.
Leukapheresis and cryopresemation ofperipheral blood cells.
RESULTS
The present studies were designed to determine if a dose of blood cells that failed to reconstitute hematopoiesis in Abbreviation: ND, not determined.
"HPP-CFC cultures initiated with 1 x lo5 cells from the leukapheresis product per plate had too many colonies to accurately enumerate HPP-CFC. However, it was estimated that in each of the three culture plates there were more than 10 HPP-CFC per plate.
vivo, could reproducibly engraft and rescue lethally irradiated animals when taken from normal untreated animals, SCF-treated animals. Three baboons were transplanted with 1.02 & 0.01 X lo8 per kg (mean +-SEM, range = 1.02 to 1.03 x lo*) of PBMNC that had been collected by leukapheresis on day 10 or 11 (the last day of treatment) of SCF administration (see
org From
Materials and Methods). The total number of leukapheresed cells infused was based on the cell counts and the proportion of mononuclear cells present at the time the leukapheresed cells were cryopreserved. At the time that the PBMNC were collected, the number of CFC in the circulation had increased significantly (Table l) , as previously reported." The frequency of CD34+ cells in the light scatter window characteristic of blast cells or monocyte-like cellsz8 increased with SCF treatment from 0.1% to 0.3% (mean * SEM = 0.2% ? 0.1%) before treatment to 1.0% to 3.3% (mean SEM = 2.2% f 0.7%) on day 7 of SCF. In the cells collected by leukapheresis, the frequency of CD34+ cells in the population with light scatter characteristics of blast-like or monocyte-like cells was 5.6% f 2.1% (mean ? SEM). Twenty-four to 38 days later, the frequency of CFC in the peripheral blood had decreased to the same levels detected before SCF administration (Table 1 ).
Stem Cell Previous studies have shown that 7 to 14 days are required for circulating CFC to return to pretreatment levels after SCF a d m i n i s t r a t i~n .~~ The cryopreserved autologous PBMNC were infused into the animals after they had been treated with a single dose of 1,020 cGy TBI.
All three animals had evidence for rapid trilineage engraftment (Fig 1) and two remain alive more than 180 and 245 days posttransplant with stable reconstitution of all hematopoietic lineages. All animals showed rapid recovery of peripheral blood white blood cell counts ( Table 2 ). The rate of recovery of stable peripheral blood platelet counts posttransplant was variable. All animals had evidence for trilineage engraftment within 17 to 32 days based on either recovery of platelet counts or marrow biopsy (Figs 1 and 2) . The first animal transplanted had no infectious complications, and required only a single transfusion for platelet support. Platelet reconstitution was stable throughout the Values in table are the days posttransplant when the total white blood cell count (WBC) and the absolute neutrophil count (ANC) first reached the levels indicated in number of cells per microliter of blood, and the first day when the platelet count was self sustaining. Animal 90030 had 4 days in which the WBC was 500 or 600/pL and 7 days with ANC between 100 and 2OO/pL.
Abbreviation: NR, not reached.
period of posttransplant observation with platelet counts of 183 t 8 x 103/pL (mean t SEM of 17 observations, range = 130 to 256 x 103/pL). The other two animals had evidence of megakaryocytopoiesis by marrow biopsy early after transplantation but remained thrombocytopenic for prolonged periods, presumably from platelet consumption secondary to significant infectious complications. One animal developed enterococcal sepsis on day + 14 and died on day +32 posttransplant. Multiple marrow biopsies obtained at necropsy showed a hypercellular marrow (150% normal cellularity, megakaryocytes 40% normal) with trilineage engraftment (Fig 2) . A second animal developed an infection along the track of its central venous catheter with sepsis and metastatic abscesses and then a severe septic thrombophlebitis associated with a peripheral venous line. Marrow biopsies obtained at days 17,34, and 70 posttransplant showed trilineage engraftment with loo%, loo%, and 150% of normal marrow cellularity, respectively (Fig 2) . Megakaryocytes were loo%, 30%, and 150% of normal on days 17,34, and 70, respectively. With disappearance of the infectious complications, this animal's thrombocytopenia resolved, and throughout the remaining period of observation the platelet counts averaged 200 t 18 x 103/pL (mean t SEM of 11 observations, range = 120 to 293 x 10' 1
These findings contrast with four control animals that were transplanted w i t h 1.02 to 1.04 x 10R/kg (mean t SEM = 1.03 t 0.01 x 10R/kg) of PBMNC collected by leukapheresis with no previous SCF treatment (Table 1 ). These cells contained substantially fewer CFC than did those from collected SCF-treated animals. Because it was thought possible that treatment with SCF might induce a radioprotective state, one control animal was treated with SCF (200 pg/kg/d) for a period of 11 days after its PBMNC had been collected. This animal was then transplanted 25 days after the last dose of SCF, similar to experimental animals transplanted with SCF-stimulated cells. None of the control animals showed evidence for engraftment after transplantation and none of them survived past 38 days (Table 2 ). Marrow biopsies obtained at necropsy demonstrated hypocellular marrows (Fig 2) . These findings suggest that 1 x lox PBMNC from untreated animals normally contain insufficient progenitor and precursor cells to rescue baboons from the lethal effects of TBI.
ILL).
DISCUSSION
The present study confirmed previous findings that treatment with SCF stimulates increased numbers of hematopoi- For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From etic CFC and CD34+ cells to appear in blood of baboons.24 Importantly, it showed that cells capable of engrafting lethally irradiated baboons are increased in the circulation by treatment with SCF. The same dose of PBMNC (1 X 1@/ kg) isolated from untreated animals was insufficient to rescue lethally irradiated recipients. Further, the SCF treatment itself did not appear to result in protection from the lethal effects of the TBI. During leukapheresis, 3 to 8 times the number of PBMNC used for transplantation were collected from both SCF-treated and untreated control animals in this study. Thus, the single leukapheresis of each SCF-treated animal resulted in the collection of enough cells to potentially perform multiple transplants. Whether transplantation of all the cells collected from SCF-treated animals would have led to more rapid hematopoietic reconstitution, and whether all of the cells collected from untreated controls were sufficient to rescue animals following TBI was not determined.
Murine SCF has been reported to have a significant radiation protective effect in mice, but only when administered immediately before irradiation, within 20 hours, but it does not have this effect when administered at the time of irradiation, more than 24 hours before irradiation, or after i r r a d i a t i~n .~~ In the present studies, one control animal treated with SCF before transplantation did not show evidence for protection. It is unlikely that the recovery of hematopoiesis after transplantation of the SCF-treated primates in this study (transplanted 24 to 38 days after stopping SCF treatment) was a result of a radiation protective effect of SCF. However, radiation protection studies similar to those done for mice have not been performed in primates.
In the present studies, the dose of PBMNC transplanted was limited to 1 x 108/kg. In dogs, transplantation of I 1 X 108/kg of autologous PBMNC has resulted in engraftment of I 25% of the animals, while transplantation of 2 4 x lo8 autologous PBMNC/kg has been required to rescue all animals after lethal TBI.8,9,11 In mice, transplantation of unfractionated whole blood from untreated animals suggests that similar numbers of cells per kilogram are required to rescue lethally irradiated mice, that cells of donor origin can be demonstrated in the animals with stable hematopoietic reconstitution, and that recombinant human granulocyte colony-stimulating factor (G-CSF) increases the number of these transplantable cells in the circ~lation.'~ The mechanisms that regulate the trafficking of hematopoietic CFC in vivo is poorly understood. Treatment with G-CSF and GM-CSF appears to produce a transient increase in circulating CFC.12-*8,20,22 However, this may coincide with decreased frequencies of CFC in marrow.12 In contrast, increases in circulating CFC stimulated by SCF have persisted as long as SCF is administered (28 days being the longest period studied thus far) and marrow CFC have been increased, but CFC return to baseline levels in blood within 7 to 14 days after stopping SCF administration." In humans, administration of specific recombinant human growth factors, including G-CSF and GM-CSF, after chemotherapy has produced increases in the number of CFC in the circulation over that observed after chemotherapy alone.12-20,22 It has been observed that blood cells collected from patients after such treatment can enhance the rate of hematopoietic reconstitution when transplanted along with autologous marrow cells, as well as the rate of hematopoietic recovery after high-dose chemotherapy. They also have been found to contain cells capable of engrafting in patients following myeloablative chemotherapy and radiation therapy. Although the cells in blood that have this activity have not been precisely defined, it is thought that they reside within a population of cells that express the CD34 antigen and are phenotypically similar to those found in marrow.16J7 Administration of SCF as well as G-CSF can increase the number of detectable CD34+ cells in the circulation. It will be necessary to isolate these CD34+ cells from blood to determine if they have the same in vivo biologic potentials as marrow-derived CD34+ The major unresolved questions are to what extent true hematopoietic stem cells, cells that mediate long-term stable hematopoietic reconstitution, circulate, how specific hematopoietic growth factors influence the trafficking of stem cells, and how these circulating stem cells differ from their marrow derived counterparts.
The present study shows that SCF stimulates the circulation of cells responsible for engrafting lethally irradiated baboons. SCF may have clinical utility in stimulating the circulation of cells that are useful for inducing rapid engraftment after transplantation. To what extent the SCF-stimulated PBMNC can provide long-term engraftment (ie, include stem cells) will require further studies in which the contribution of donor cells to specific lineages and the longevity of engraftment can be determined.
